Investigating the efficacy of osimertinib and crizotinib in phase 3 clinical trials on anti-cancer treatment-induced cardiotoxicity: are real-world studies the way forward?

BACKGROUND. Oncology clinical trials demonstrate the risk of cardiotoxicity but are not sufficient to reveal the true risk. In this article, we compared the incidence of cardiotoxicity of crizotinib and osimertinib from a real-world study to data reported by phase 3 clinical trials. METHODS. Data fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobat, Hasan, Elkonaissi, Islam, Foreman, Emma, O’Brien, Mary, Dorak, Mehmet Tevfik, Nabhani-Gebara, Shereen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068407/
https://www.ncbi.nlm.nih.gov/pubmed/35167392
http://dx.doi.org/10.1177/10781552221077417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068407/
https://www.ncbi.nlm.nih.gov/pubmed/35167392
http://dx.doi.org/10.1177/10781552221077417

Ejemplares similares